IGKV2D-30: A Potential Drug Target and Biomarker (G28881)

Target Name: IGKV2D-30

NCBI ID: G28881

Other Name(s): immunoglobulin kappa variable 2D-30 | Immunoglobulin kappa variable 2D-30 | IGKV2D30 | A1

IGKV2D-30: A Potential Drug Target and Biomarker

Immunoglobulin kappa variable 2D-30 (IGKV2D-30) is a type of antibody that is found in the bloodstream of individuals with rheumatoid arthritis (RA). It is also sometimes found in individuals with lupus and other autoimmune disorders. IGKV2D-30 has been shown to play a role in the development and progression of these conditions, which has led to its potential as a drug target or biomarker.

IGKV2D-30 is a single-chain variable region antibody that contains a variable region that consists of a variable light chain and a variable heavy chain. The variable light chain is the portion of the antibody that is involved in the antigen recognition, while the variable heavy chain carries the majority of the immunoglobulin molecules. IGKV2D-30 has a molecular weight of approximately 180 kDa and a pre-fusion width of 120 kDa.

IGKV2D-30 has been shown to play a role in the development and progression of RA. Studies have shown that individuals with RA are more likely to have higher levels of IGKV2D-30 in their bloodstream compared to individuals without RA. Additionally, individuals with RA who have high levels of IGKV2D-30 are more likely to have more severe symptoms of the condition.

IGKV2D-30 has also been shown to play a role in the development and progression of lupus. Studies have shown that individuals with lupus are more likely to have higher levels of IGKV2D-30 in their bloodstream compared to individuals without lupus. Additionally, individuals with lupus who have high levels of IGKV2D-30 are more likely to have more severe symptoms of the condition.

The potential implications of IGKV2D-30 as a drug target or biomarker are significant. If IGKV2D-30 can be effectively targeted or measured, it could potentially be used as a diagnostic tool for RA and other autoimmune disorders. Additionally, if IGKV2D-30 can be used as a drug target, it could potentially lead to the development of new treatments for these conditions.

In conclusion, IGKV2D-30 is a potential drug target and biomarker for RA and other autoimmune disorders. Further research is needed to fully understand its role in the development and progression of these conditions, as well as its potential as a diagnostic or therapeutic tool.

Protein Name: Immunoglobulin Kappa Variable 2D-30

Functions: V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

More Common Targets